Jefferies Financial Group set a €90.00 ($104.65) price objective on Sanofi (EPA:SAN) in a report released on Friday morning, Borsen Zeitung reports. The firm currently has a buy rating on the stock.
SAN has been the subject of several other reports. Deutsche Bank set a €93.00 ($108.14) price objective on shares of Sanofi and gave the company a buy rating in a report on Friday, April 5th. Goldman Sachs Group set a €77.00 ($89.53) price objective on shares of Sanofi and gave the company a neutral rating in a report on Friday, April 26th. HSBC set a €82.00 ($95.35) target price on shares of Sanofi and gave the company a neutral rating in a research note on Thursday, May 9th. JPMorgan Chase & Co. set a €81.00 ($94.19) target price on shares of Sanofi and gave the company a neutral rating in a research note on Monday, June 3rd. Finally, UBS Group set a €79.00 ($91.86) target price on shares of Sanofi and gave the company a neutral rating in a research note on Friday, April 26th. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of €85.67 ($99.61).
Sanofi stock opened at €77.68 ($90.33) on Friday. Sanofi has a 12-month low of €63.09 ($73.36) and a 12-month high of €92.97 ($108.10).
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.